Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock

Company Overview - C4 Therapeutics, Inc. (NASDAQ:CCCC) is a biopharma company focused on developing products that degrade disease-causing proteins and oncology products like CFT8919 for lung cancer [3] Financial Performance - In Q4, C4 Therapeutics reported revenue of $11.016 million, significantly exceeding estimates of $4.48 million [2] - The company has a cash position of $297.1 million, up from $199.8 million in the previous quarter, indicating sufficient funding for ongoing research initiatives [2] Analyst Ratings - All 8 analysts covering C4 Therapeutics are bullish, with a median price target of $7, suggesting significant upside potential [1] - Guggenheim analyst Bradley Canino maintained a $7 price target, while Barclays analyst Etzer Darout raised his target from $5 to $7 [1]